Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 57 Results

Title
Intervention Indication Therapeutic Area Year Actions
Abemaciclib for early breast cancer – adjuvant treatment Abemaciclib (LY2835219; Verzenio; CC-115) Breast cancer Breast Cancer 2020 View  |  Download
Abemaciclib in combination with fulvestrant for advanced or metastatic breast cancer after prior endocrine therapy Abemaciclib (LY2835219; Verzenio; CC-115) , Fulvestrant (Faslodex) Breast cancer Breast Cancer 2017 View  |  Download
Abemaciclib with fulvestrant for HR+/HER2- locally advanced or metastatic breast cancer after CDK4/6 inhibitor and endocrine therapy Abemaciclib (LY2835219; Verzenio; CC-115) , Fulvestrant (Faslodex) Breast cancer Breast Cancer 2024 View  |  Download
Alpelisib in Combination with Fulvestrant for Advanced HR Positive, HER2-negative Breast Cancer in Men and Postmenopausal Women Alpelisib (BYL719; Piqray) , Fulvestrant (Faslodex) Breast cancer Breast Cancer 2017 View  |  Download
Atezolizumab in addition to paclitaxel for inoperable, locally advanced or metastatic triple negative breast cancer – first-line Atezolizumab (Tecentriq; MPDL3280A) , Paclitaxel (Taxol; paclitaxel albumin) Breast cancer Breast Cancer 2019 View  |  Download
Atezolizumab in combination with nab-paclitaxel as neoadjuvant treatment for early stage triple-negative breast cancer Atezolizumab (Tecentriq; MPDL3280A) , Nab-Paclitaxel (Abraxane; ABI 007; ABI-007) Breast cancer Breast Cancer 2018 View  |  Download
Atezolizumab in combination with Nab-paclitaxel for unresectable, locally advanced or metastatic triple-negative breast cancer – first line Atezolizumab (Tecentriq; MPDL3280A) , Nab-Paclitaxel (Abraxane; ABI 007; ABI-007) Breast cancer Breast Cancer 2018 View  |  Download
Atezolizumab with chemotherapy for treating recurrent triple-negative breast cancer Atezolizumab (Tecentriq; MPDL3280A) , Chemotherapy Breast cancer Breast Cancer 2022 View  |  Download
Benegrastim for treating chemotherapy-induced neutropenia in women with breast cancer Benegrastim Breast cancer Breast Cancer , Immunology , Toxicology 2022 View  |  Download
Capivasertib with fulvestrant for HR+/HER2- locally advanced or metastatic breast cancer Capivasertib , Fulvestrant (Faslodex) Breast cancer Breast Cancer 2023 View  |  Download
1 2 3 5 6
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications